Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner - EVP & CFO Amy Peterson - EVP, Product Development, Medical Affairs & Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - EVP, Commercial Conference Call Participants Asthika Goonewardene - Truist Chi Fong - Bank of America Silvan Tuerkcan - Citizens JMP Michael Schmidt - Guggenheim Securit ...

Exelixis (EXEL) reported $539.54 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 14.3%. EPS of $0.47 for the same period compares to $0.10 a year ago.The reported revenue represents a surprise of +9.84% over the Zacks Consensus Estimate of $491.22 million. With the consensus EPS estimate being $0.42, the EPS surprise was +11.90%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...

Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 11.90%. A quarter ago, it was expected that this drug developer would post earnings of $0.37 per share when it actually produced earnings of $0.84, delivering a surprise of 127.03%. Over the last four quarters, the compan ...

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenue ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

The midcap biotech just became an even better buy.There is a loose relationship between price and quality on the stock market. Penny stocks are overwhelmingly regarded as high risk, while many larger-cap shares trade at high prices.Still, it's possible to find solid businesses whose share prices aren't too high -- perhaps following a recent stock split or because the market is ignoring their potential, or for some other reason. In other words, there is no need to break the bank to invest in quality companie ...

Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29 ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE . I have embraced employing covered call holdings around most of my small and midcap biotech positions over the past five to six years. Option premiums around this high-beta part of ...

文章核心观点 - 该文章作者是一名资深的生物科技和医疗保健投资分析师,拥有多年的临床经验和工商管理硕士学位 [1] - 作者自2017年以来一直在Seeking Alpha上分享自己的分析,这是他最喜欢做的事情之一 [1] - 作者利用风险收益图表和折现现金流分析来突出投资机会和风险 [1] - 作者采用"哑铃策略",90%投资于国债和ETF等安全资产,10%投资于高增长股票,将风险管理放在首位 [1] - 由于市场相当有效,收益可能随机,作者从"超级预测"和"抗脆弱"中获得灵感,专注于概率预测和稳健策略,最小化风险同时最大化收益 [1] 免责声明 - 作者没有持有任何提及公司的股票、期权或类似衍生工具,也没有在未来72小时内进行任何此类持仓的计划 [2] - 本文是作者自己撰写的,表达的是自己的观点,作者没有从Seeking Alpha以外获得任何报酬 [2] - 作者与本文提及的任何公司都没有任何业务关系 [2] - 本文仅提供信息性内容,不应被视为对所述公司的详尽分析 [2] - 本文中的预测和意见基于作者的分析,反映了一种概率方法,而非绝对确定性 [2] - 尽管已尽力确保信息的准确性,但可能会出现无意的错误 [2] - 读者应独立核实信息并进行自己的研究,投资股票存在固有的波动性、风险和投机性 [2] - 在做出任何投资决策之前,读者都应该进行彻底的研究并评估自己的财务状况 [2] - 作者不对因使用或依赖本文内容而造成的任何财务损失负责 [2] Seeking Alpha免责声明 - 过去的业绩并不能保证未来的结果 [3] - 本网站不会就任何投资是否适合某位投资者提供任何建议或意见 [3] - 本网站上的任何观点或意见可能不代表Seeking Alpha整体的观点 [3] - Seeking Alpha不是持牌的证券交易商、经纪人或美国投资顾问或投资银行 [3] - 本网站的分析师是第三方作者,包括专业投资者和非专业投资者,可能未经任何机构或监管机构的认证 [3]

Exelixis (EXEL) shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks. Exelixis' shares gained on a favorable court ruling against MSN Laboratories for a generic product of lead drug Cabometyx (related to cabozantinib). The Delaware District Court ruled in Exelixis' favor, rejecting MSN's challenge to three listed patents rela ...